# Tyra Biosciences

Source: https://onco.cc/companies/tyra-biosciences/  
OnCo record `tyra-biosciences` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Tyra Biosciences designs precise pills against a family of growth-signal proteins called FGFRs, which are faulty in some bladder, liver and bile duct cancers and in a bone growth disorder.

## Summary

Tyra Biosciences is a Carlsbad, California company developing next-generation FGFR inhibitors designed to avoid resistance mutations and to spare related kinases. Its lead candidate, dabogratinib (TYRA-300), is an FGFR3-selective inhibitor in clinical development for non-muscle invasive bladder cancer and low-grade upper tract urothelial cancer, and in the phase 2 BEACH301 study in achondroplasia. TYRA-430 (FGFR4/3) is in the phase 1 SURF431 study in advanced hepatocellular carcinoma and other solid tumours, and TYRA-200 (FGFR1/2/3) is in the phase 1 SURF201 study in intrahepatic cholangiocarcinoma and other FGFR2-altered tumours. Tyra completed its Nasdaq IPO in September 2021, raising 198.7 million US dollars gross.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: Carlsbad, CA
- Type: biotech
- Website: https://tyra.bio/
- Ticker: TYRA

## Notes

- Founding year and later financings not sourced. Investor news pages (ir.tyra.bio) returned 403.

## Sources

- Official website: https://tyra.bio/
- Pipeline: https://tyra.bio/pipeline/
- IPO closing 8-K (SEC): https://www.sec.gov/Archives/edgar/data/1863127/000119312521276124/d220261d8k.htm

## Connected records

- cancers: [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- technologies: [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- targets: [FGFR2](https://onco.cc/targets/fgfr2/)
- drugs: [TYRA-300](https://onco.cc/drugs/tyra-300/)
- trials: [Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer](https://onco.cc/trials/nct06995677/), [Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Carcinoma and Other Solid Tumors With FGFR3 Gene Alterations](https://onco.cc/trials/nct05544552/)

---
JSON: https://onco.cc/api/v1/entities/tyra-biosciences.json